<DOC>
	<DOCNO>NCT01654822</DOCNO>
	<brief_summary>This study aim prove , one-time topical spray cervix , AV2-DM effective antiviral reduce short term ( 3 month ) human papillomavirus ( HPV ) infection . - Primary endpoint : significant drop viral load AV2-DM versus placebo - Secondary endpoint : number patient adverse event</brief_summary>
	<brief_title>AV2 Antiviral Spray Versus Placebo Human Papillomavirus Cervix Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . Women 25 40 year 2 . Patient recently ( 6 month ) Quantitatively ( Viral Load ) Qualitatively ( HPV type ) diagnose HPV . 3 . Ability willingness participate study . 4 . Subject agree refrain use prescription supplemental antiviral medication without obtain permission Treating Doctor . 5 . Voluntary write informed consent . 1 . Subject vaccinate HPV 2 . Interval delivery T0 le 3 month 3 . Subject gynecologic surgical intervention T0 T1 4 . Subject diagnosed HPV negative T0 5 . Subject ( adeno ) carcinoma situ . 6 . Females child bear potential use reliable , medically accept method birth control 7 . Pregnant breastfeed female , woman plan become pregnant trial . 8 . Medical history immunosuppression radiotherapy , chemotherapy , immunomodulatory drug , HIV . 9 . Participation another clinical trial concern HPV infection within 6 month application AV2DM antiviral spray . 10 . Medical history severe disease like hepatitis , renal liver dysfunction , cardiovascular , gastrointestinal , malignant tumor ( ) , psychiatric disorder etc. , might influence assessment conduct trial discretion investigator . 11 . Intake application antiviral prohibit concomitant medication within 30 day prior application AV2 , patient plan take drug trial . 12 . Known suspected allergic adverse response investigational product AV2DM Antiviral spray , 's component , olive oil dlimonene . 13 . Inability follow study protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HPV</keyword>
	<keyword>cervix</keyword>
</DOC>